Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Luis Rosero-Bixby has a total of 354 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Aging Out of the Blue: Region-Specific Epigenetic Clock Calibration for a Blue Zone with the DNAm SuperLearner

    by Nolan Gunter, Andres Cardenas, Michael Kobor, Nicole Gladish, Julia L. MacIsaac, Kristy Dever, David Rehkopf, William Dow, Luis Rosero-Bixby, Alan Hubbard

    Epigenetic clocks estimate biological age from DNA methylation patterns at CpG sites, providing robust predictions of mortality and morbidity risk. “Blue zones”—regions of exceptional longevity—offer a unique opportunity to investigate how biological aging diverges from chronological age. However, standard clocks are typically trained on large, heterogeneous datasets, reflecting average population trends rather than region-specific dynamics. Using data from the Costa Rican Longevity and Healthy Aging Study (CRELES), we profiled DNA methylation from residents of the Nicoya blue zone ( n = 206) and a comparison population in other parts of Costa Rica ( n = 875). We propose training a SuperLearner , an ensemble machine learning approach, on the non-Nicoyan Costa Ricans to optimize predictive performance across existing clocks and flexible machine learners. Theoretically justified by its Oracle property, SuperLearner performs asymptotically as well as the best candidate predictor in the ensemble, resulting in a weighted combination of algorithms used to predict age. We then used this trained model to construct a calibrated hypothesis test comparing residual age distributions between the blue zone region and the comparison population. Comparing our approach to the five top-performing epigenetic clocks (ranked by MSE) in the Costa Rican cohort, only SuperLearner suggested age deceleration (an average of ∼ 1 year) in the non-Nicoyan reference group. Before calibration, SuperLearner showed the strongest evidence for slowed biological aging among blue zone Nicoyans, estimating a three-year reduction ( R̄ 1 = −3.05, 95% CI [−3.64, −2.46]) in epigenetic age. Calibrating with non-Nicoyan Costa Ricans improved consistency between estimates in all clocks, decreasing the estimated aging advantage in Nicoyans to about two years (Δ̂ = −1.96, 95% CI [−2.56, −1.37]). This approach provides a robust framework for estimating longevity in distinct regions when a relevant comparison population is available.

  • Open Access

    Are blue zones Disappearing?

    by S. Jay Olshansky, Steven Austad, Anne Herm, Giovanni Pes, Michel Poulain, David Rehkopf, Jean Marie Robine, Luis Rosero-Bixby, Bradley Willcox, D. Craig Willcox, et al.

    The historic rise in human longevity among long-lived national populations has slowed down in this century. One proposed explanation is that, as survival to older ages becomes more common, additional gains depend increasingly on reducing mortality at ages where the baseline hazard is dominated by biological aging, making further improvements harder to achieve without interventions that modify aging itself. If this interpretation is correct, then geographically defined longevity hotspots known as blue zones, should show early or pronounced deceleration and/or convergence as other populations catch up. We test this using period vital statistics from three widely cited blue zones: Okinawa (Japan) and in selected municipalities in Sardinia (Italy) and Nicoya (Costa Rica). We compare each blue zone to (i) its national population, and (ii) to three contemporaneous long-lived countries (a composite) with the highest period life expectancy at the time each blue zone was first reported in the scientific literature (Japan, Hong Kong, and France). Using period demographic metrics of longevity (life expectancy at age 70 [e(70)], survival (conditional survival from age 70 to 100), and the prevalence of centenarians from 1991-2019 for Okinawa, for males we found that in the year each was declared a blue zone, e(70) was an average of 9.8% higher relative to composite; conditional survival from ages 70 to 100 was ~2-fold that of composite; and the prevalence of centenarians per 100,000 in Okinawa was 2.7-fold greater than composite. Similar but highly variable patterns were observed for females. All three blue zones were revalidated here as longevity outliers in the year in which they were declared. We also found a broad deceleration in the rate of improvement in these metrics for Okinawa and Nicoya after ~2010, defined as a reduction in the slope of improvement (and in some cases a decline) compared with earlier periods. Overall, the demographic distinctiveness of the three blue zones has narrowed since their initial identification. We attribute this convergence to (1) catch-up among national and other long-lived populations, (2) a general slowdown in late-life mortality improvement consistent with increasing dominance of aging-related causes at advanced ages, and (3) cohort replacement that erodes historically favorable early-life, midlife, and behavioral exposures that characterized early-20th-century cohorts in these regions.


  • Open Access

    Sobrevida y mortalidad de pacientes con trasplante renal en Costa Rica 2019-2023

    by Allan Varela Rodríguez, Ana Teresita Barquero-Uriarte, Carolina Santamaria-Ulloa, Luis Rosero-Bixby

    Objetivo. Determinar la sobrevida y mortalidad de los pacientes que reciben trasplante renal en Costa Rica, los factores asociados a éstas y las diferencias entre hospitales. Métodos. Datos de tipo tiempo-sobrevivencia de los 292 pacientes que recibieron trasplante renal efectuados en hospitales de Costa Rica durante el periodo 2019 a 2023. Tasas de mortalidad por año-persona trasplantada. Curvas Kaplan-Meier de sobrevivencia. Riesgos relativos de morir según características estimados con regresión múltiple de Cox. Resultados. La supervivencia a 5 años postrasplante resultó de 78%; promedio de 91% para trasplantes de donante vivo y 69% de donante cadavérico. El riesgo de morir de estos últimos es críticamente alto en los primeros seis meses postrasplante, con una tasa anualizada de 26% muertes, que resulta casi seis veces mayor que en los 4,5 años siguientes y que el riesgo de pacientes con donante vivo. Los pacientes que superan con vida los primeros seis meses postrasplante tienen una mortalidad ocho veces mayor que la población en general. El número pequeño de observaciones en la base de datos no permitió identificar diferencias significativas en relación con la mortalidad entre hospitales. La mortalidad de los pacientes trasplantados durante la pandemia de Covid-19 no fue mayor que en otros años. Conclusiones. En comparación con países exitosos, la sobrevida de pacientes con trasplante renal en Costa Rica es alta y es similar a esos países para donante vivo, pero menor para donante cadavérico, esto indica que hay campo para mejorar. Los pacientes con trasplante renal son un grupo de alto riesgo de morir, especialmente en los primeros meses tras el trasplante. La existencia de un registro nacional de trasplantes ha permitido estimar por primera vez la sobrevida y mortalidad de las personas receptoras en el ámbito nacional. Es importante que este registro se mantenga actualizado y se amplíe con información que permita optimizar el programa de trasplante renal.

  • Open Access

    A cohort study of seasonality and weather-sensitivity of chronic disease biomarkers in the tropics: the Costa Rican Longevity and Healthy Aging Study (CRELES).

    by Luis Rosero-Bixby, William Dow

    Background Previous research has shown seasonality and climate-sensitivity in chronic disease biomarkers, but it hasn’t been done in tropical settings with different weather patterns. Identifying these variations can help understand the potential health consequences of global climate change. Our objective is to find seasonal variations in 13 biomarkers and their association with ambient heat and pluviosity in a tropical environment. Methods We studied within-person changes in 13 biomarkers between two measures 1.8 years apart in a nationally representative panel of 2,177 older adults in Costa Rica. We used NASA’s global databases for ambient heat and precipitation in the month previous and location of participants. To find seasonal patterns, we used sinusoidal regression, and “fixed effects” regression models for robust associations. Results The amplitude of seasonality was significant in ten of the 13 biomarkers. Total cholesterol had the widest amplitude, with a peak in late July and a trough in early December. Rainfall in the previous month didn’t show a significant association, but seven biomarkers were associated with ambient temperature. Warmer weather was linked to significant increases in total cholesterol, fasting blood glucose, creatinine, and DHEAS, and decreases in hemoglobin A1c, abdominal circumference, and telomere length. Weather variation accounted for the entirety of the seasonal variation in creatinine, DHEAS, and systolic blood pressure. Conclusion This study found significant seasonality in most biomarkers and association with ambient in a tropical environment. Research in other populations will inform generalizability, the importance of unmeasured seasonal and weather-related confounding in population-based risk factor research, and causal estimation of climate change effects on health. Extrapolating ambient heat effects, a 2°C global temperature rise by 2050 would increase total cholesterol by 7% (11% in urban areas), elevate serum creatinine by 6%, and reduce telomere length by 4%.


  • Open Access

    The COVID-19 pandemic and fertility decline in Costa Rica: A deep plunge in the first pandemic month, a decelerated decline, and a baby bust due to fleeing migrants

    by Luis Rosero-Bixby

    Using microdata from the administrative birth registry maintained by the electoral authority of Costa Rica, this paper aims to address the knowledge gap concerning childbearing during the COVID-19 pandemic in the context of rapid fertility decline since before the pandemic, as compared to the scenario in the highly developed countries. Monthly fertility rates for the period between 2018 and 2022 were estimated. The outcome of interest was a year-on-year change in these rates. The major findings of this study are as follows: (i) A short-lived baby bust in the first full month of the pandemic that is similar to falls observed in other countries (the year-on-year decrease of fertility in January 2021 was as high as 24% for some groups); (ii) a pandemic-associated deceleration in the fertility decline, which could be interpreted as a baby boom if the counterfactual were a continuation of the recent pre-pandemic declining trend; (iii) hints of a baby boom later in the pandemic in communities with low socioeconomic status, and especially, in families with several children, which could come from unwanted pregnancies; and (iv) an anomalous drop in births from foreign-born mothers delivered during the first 9 months of the pandemic, which probably stemmed from pandemic-motivated migration out of the country. The fertility plunge in January 2021 seems to be a response to the hardships caused by pandemic mitigation measures in April 2020, as well as by the uncertainties and fears concerning COVID-19, rather than the response to the physiological harm of the disease itself. The native-born Costa Ricans saw some of the lowest total birth rates in the world during the pandemic: 1.14 and 1.13 births per woman in 2021 and 2022, respectively. These rates would have been even lower if the sharp birth decline observed before the pandemic had continued during the two pandemic years under study.


  • Open Access

    Centenarian clocks: epigenetic clocks for validating claims of exceptional longevity

    by Eric Dec, James Clement, Kaiyang Cheng, George M. Church, Michael B. Fossel, David H. Rehkopf, Luis Rosero-Bixby, Michael S. Kobor, David Ts. Lin, Ake T. Lu, et al.

    Claims surrounding exceptional longevity are sometimes disputed or dismissed for lack of credible evidence. Here, we present three DNA methylation-based age estimators (epigenetic clocks) for verifying age claims of centenarians. The three centenarian clocks were developed based on n = 7039 blood and saliva samples from individuals older than 40, including n = 184 samples from centenarians, 122 samples from semi-supercentenarians (aged 105 +), and 25 samples from supercentenarians (aged 110 +). The oldest individual was 115 years old. Our most accurate centenarian clock resulted from applying a neural network model to a training set composed of individuals older than 40. An epigenome-wide association study of age in different age groups revealed that age effects in young individuals (age < 40) are correlated (r = 0.55) with age effects in old individuals (age > 90). We present a chromatin state analysis of age effects in centenarians. The centenarian clocks are expected to be useful for validating claims surrounding exceptional old age.


  • Open Access

    The COVID-19 pandemic and fertility decline in Costa Rica: A brief plunge due to psychosocial and economic factors and a baby bust driven by migration decisions

    by Luis Rosero-Bixby

    The national birth registry shows a substantial baby bust in 2021 – the first full year plus nine months into the COVID-19 pandemic. The fertility of native Costa Rican women dropped by 13%. This decrease did not deviate from pre-existing fertility trends. A brief plunge in conceptions during the first full month of the pandemic (April 2020) decreased the fertility rate in January 2021 by as much as 24% for some groups. This plunge was a response to the hardships caused by pandemic mitigation measures as well as uncertainties and fears concerning the novel disease rather than to the physiological harm of the disease itself. The 2021 decrease in births among immigrant women (who contribute one-fifth of the birth rate) was 78% larger than among native women, driven mostly by pandemic-induced migration decisions. The data hint at a pandemic baby boom in low-SES communities and, especially, in families with several children.

  • Open Access

    The Effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca Vaccines to Prevent Severe COVID-19 in Costa Rica: Nationwide, Ecological Study of Hospitalization Prevalence

    by Luis Rosero-Bixby

    Background: The Costa Rican COVID-19 vaccination program has used Pfizer-BioNTech and Oxford-AstraZeneca vaccines. Real-world estimates of the effectiveness of these vaccines to prevent hospitalizations range from 90%-98% for two doses and from 70%-91% for a single dose. Almost all of these estimates predate the Delta variant. Objective: The aim of this study is to estimate the dose-dependent effectiveness of COVID-19 vaccines to prevent severe illness in real-world conditions in Costa Rica, after the Delta variant became dominant. Methods: This observational study is a secondary analysis of hospitalization prevalence. The sample is all 3.67 million adult residents living in Costa Rica by mid-2021. The study is based on public aggregated data of 5978 COVID-19–related hospital records from September 14, 2021, to October 20, 2021, and 6.1 million vaccination doses administered to determine hospitalization prevalence by dose-specific vaccination status. The intervention retrospectively evaluated is vaccination with Pfizer-BioNTech (78%) and Oxford-AstraZeneca (22%). The main outcome studied is being hospitalized. Results: Vaccine effectiveness against hospitalization (VEH) was estimated as 93.4% (95% CI 93.0-93.9) for complete vaccination and 76.7% (95% CI 75.0-78.3) for single-dose vaccination among adults of all ages. VEH was lower and more uncertain among older adults aged ≥58 years: 92% (95% CI 91%-93%) for those who had received full vaccination and 64% (95% CI 58%-69%) for those who had received partial vaccination. Single-dose VEH declined over time during the study period, especially in the older age group. Estimates were sensitive to possible errors in the population count used to determine the residual number of unvaccinated people when vaccine coverage is high. Conclusions: The Costa Rican COVID-19 vaccination program that administered Pfizer-BioNTech and Oxford-AstraZeneca vaccines seems to be highly effective at preventing COVID-19–related hospitalization after the Delta variant became dominant. Even a single dose seems to provide some degree of protection, which is good news for people whose second dose of the Pfizer-BioNTech vaccine was postponed several weeks to more rapidly increase the number of people vaccinated with a first dose. Timely monitoring of vaccine effectiveness is important to detect eventual failures and motivate the public to get vaccinated by providing information regarding the effectiveness of the vaccines.